BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)

The summary for the BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed): This FOA seeks applications for unique and innovative recording and/or modulation technologies that are in the earliest stage of development, including new and untested ideas that are in the initial stages of conceptualization. Some projects may aim to increase recording or modulation capabilities by many orders of magnitude, while others may aim to improve the precision and selectivity of recording or modulation (also referred to as stimulation, perturbation, or manipulation). A wide range of modalities are appropriate including acoustic, chemical, electrical, magnetic, and optical, as well as the use of genetic tools. Invasive or non-invasive approaches are sought that will enable large-scale recording and/or precise manipulation of neural activity, and that would ultimately be compatible with experiments in humans or behaving animals. Applications are encouraged from any qualified individual, including chemists, physicists, engineers, theoreticians, materials scientists, and others from fields not typically involved with neuroscience research. This FOA requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.

Federal Grant Title:	BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Education Health Income Security and Social Services
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-EY-23-001
Type of Funding:	Grant
CFDA Numbers:	93.173, 93.213, 93.242, 93.273, 93.279, 93.286, 93.853, 93.865, 93.866, 93.867
CFDA Descriptions:	Information not provided
Current Application Deadline:	June 15th, 2026
Original Application Deadline:	June 15th, 2026
Posted Date:	September 19th, 2023
Creation Date:	September 19th, 2023
Archive Date:	July 21st, 2026
Total Program Funding:
Maximum Federal Grant Award:	$400,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	September 20th, 2023

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/rfa-files/RFA-EY-23-001.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional); • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Medical Rehabilitation Research Resource (P50 Clinical Trial Optional); • Optimizing Health of Children and Adolescents with Perinatal HIV Exposure (U19 Clinical Tr...; • NIDCD Patient-Oriented Research Grant (R21); • Cell Lineage and Developmental Studies in Hearing and Balance; • Structural Analyses of the Ligand-Binding Properties of Taste and Smell Receptors
More Grants from the National Institutes of Health: • Hazardous Materials Worker Health and Safety Training (U45 Clinical Trials Not Allowed); • Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional); • Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed); • Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Opti...; • Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Opti...